Cell therapies have become a highly active area of clinical development in oncology with CAR-T therapies being the most advanced. The first CAR-T therapies were approved in the U.S. in 2017, followed by approvals in the EU and Japan in 2018 and 2019 respectively. China had its first approval in 2021.

Thus far CAR-T approvals have been limited to hematologic tumors as efficacy in solid tumors is limited by an immune-suppressive tumor microenvironment, limited intra-tumoral migration, and the heterogeneous nature of tumor-specific antigens.

To overcome challenges in both solid tumors and in hematologic tumors, development is underway to increase the clinical benefit of CAR-T therapies through novel modified CAR-Ts and CAR-T combinations.

This infographic provides an overview of current CAR-T trials by clinical phase of development and by trial design. Whilst hematologic trials still dominate, there is hope that these novel treatments can bring benefits to patients with solid tumors with a large number of Phase I trials underway.

Cerner Enviza
an Oracle company

Data is pulled from CancerMPact®: Cancer Landscape and Future Trends and Insights modules and is accurate as of 1st September 2022. Cerner Enviza aims to accelerate the discovery, development and delivery of extraordinary insights and therapies to improve everyday health for all people globally. By combining decades of innovation, life sciences knowledge and collaborative research, Cerner Enviza provides data-driven solutions and expertise that help bring remarkable clarity to healthcare’s most important decisions. For more information on Cerner Enviza, visit www.cernerenviza.com.

Copyright © 2022 Cerner Corporation. All Rights Reserved.

*Rest of world